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ABSTRACT. The tumoral uptake of fluorine-18-deoxyglucose (FDG) is based upon enhanced glycolysis.
Following injection, FDG is phosphorylated and trapped intracellularly. An important mechanism to
transport FDG into the transformed cell is based upon the action of glucose transporter proteins; furthermore,
highly active hexokinase bound to tumor mitochondria helps to trap FDG into the cell. In addition, enhanced
FDG uptake may be due to relative hypoxia in tumor masses, which activates the anaerobic glycolytic
pathway. In spite of these processes, FDG uptake is relatively aspecific since all living cells need glucose.
Clinical use is therefore recommended in carefully selected patients. NUCL MED BIOL 25;4:317–322, 1998.
© 1998 Elsevier Science Inc.
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INTRODUCTION
Fluorine-18 deoxyglucose (FDG) is used by many centers for tumor
imaging and assessment of the metabolic state of malignant lesions.
There is ample evidence that the accumulation of FDG is based on
enhanced glycolysis, which has often been associated with the
growth rate and the malignancy potential of the tumor. Although
many patients have benefited from scintigraphy with FDG, one
should be aware of the diagnostic limitations associated with the use
of this tracer. A greater understanding of this behaviour not only
serves a scientific goal but it also helps to understand scintigraphic
patterns observed under clinical circumstances in a better way.
To this end, this article reviews two major aspects of FDG-
scintigraphy: First, it provides an overview of tumor biology associated
with glucose metabolism; second, it relates the relevant biological facts
to characteristics of FDG in clinical tumor-scanning.
ON THE ORIGIN OF CANCER
How cancer arises is no longer a secret. According to modern
insights, a tumor consists of cells in which a transformation has
taken place owing to exposure to environmental factors, which may
cause damage or alteration of the cellular DNA. Such factors
include viruses, bacteria, parasites, a variety of chemicals and both
ultraviolet and ionizing radiation. Among these carcinogenic
agents, two important types have been recognized. First are those
agents that damage genes or parts of genes that control cell
proliferation and migration, and second are those agents that
promote the growth of tumor cells or their precursor cells. In
general, carcinogens cause specific cell functions to disappear and
new functions to develop. Also, cell morphology may change, and
the more the morphological grade declines during the transforma-
tion process the more the cell develops different characteristics,
such as altered membrane properties, cell-to-cell interactions, and
cell metabolism.
Gene Alterations
Two classes of genes play a major role in carcinogenesis: proto-
oncogenes and suppressor genes. The first class of genes encourages
cell enlargement and division, whereas the second can inhibit this
proliferation. After a gene mutation, proto-oncogenes may become
oncogenes, which are carcinogenic, leading to excessive multipli-
cation due to uncontrolled overproduction of growth-stimulating
proteins. Such proteins are involved in the pathways transducing
growth signals from specific transporters on the outside of the cell
through the cytoplasm to the nucleus. One of the most well-known
oncogene is the ras oncogene, which produces proteins present in
about a quarter of all human cancers (7, 40).
Tumor-suppressor genes counter the action of oncogenes and
protect the organism from uncontrolled undifferentiated growth.
Once mutated these suppressor genes may no longer produce
proteins that inhibit this excessive cell growth. Therefore, inherited
mutations in suppressor genes bring about a high cancer risk (52).
The inactivated suppressor gene does not stop abnormal cell growth
and a tumor may arise. The p53 gene on chromosome 17 is a
suppressor gene that encodes for a protein able to inactivate ras and
viral oncogenic proteins, thus reducing the probability that a
normal cell transforms into a malignant cell (14). In certain families
with high occurrence of breast carcinoma, a correlation with
hereditary mutations of the p53 gene has been demonstrated (19).
Recently, a direct relationship was shown between lung cancer and
p53 mutations stemming from carcinogens cigarette smoke con-
tained in (13).
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Characteristics of Tumor Cells
Tumor cells show a continuous multiplication, even when normal
cells are at rest. They need less growth factor than do normal cells
to achieve the same level of growth rate, and some tumor cells even
have autocrine stimulation, producing both growth factors and their
transporters. With higher growth rates, more mitoses are present,
and the number of cells being in the S-phase will be relatively
higher. With more cells in the S-phase the tissue needs more
material to produce DNA.
Compared to a normal cell, a tumor cell is more rounded, with
fewer attachments to the substratum and to other cells. Malig-
nant cells may have distinct alterations in their surface protein,
which promotes detachment from the original location. Thus,
they may invade surrounding tissue and migrate to other, more
remote tissues, establishing metastases. An example of an adhe-
sion molecule that plays a role in the ability of the tumor cell to
detach is E-cadherin (39).
Another feature of cancer cells is that they do not exhibit
anchorage dependence. Normal cells need to adhere to the extra-
cellular matrix in order to proliferate, and certain surface proteins
(integrins) are involved in this attachment. If normal cells detach
from the matrix, proliferation ceases and cell death occurs (apopto-
sis). Tumor cells do not exhibit this suicidal behaviour. They
maintain their function, staying viable in circulation (39).
Transformed cells have fewer differentiated membranes and the
membrane transporters are also less differentiated. This phenome-
non is well-known in breast-cancer patients whose response to
hormonal treatment diminishes with altered estrogen transporters
(25). In addition, it appears that perfusion varies largely throughout
the tumor. Its continuous growth, radially from the center, causes a
higher perfusion in the dividing cells in the outer parts of the tumor
bulk than in the core. This inner part is relatively hypoxic, which
may result in necrotic areas and a virtually nonperfused necrotic
mass. Also, there are intermittent periods of decreased flow alter-
nated with resumption of flow, sometimes even in the opposite
direction. These facts result in a very heterogeneous (vascular)
morphology.
GLUCOSE UPTAKE IN TUMOR CELLS
Glucose assumes a central role among the fuels for cellular energy
metabolism. Warburg was among the first to demonstrate that
tumor cells have an altered glucose metabolism (48). Even under
aerobic conditions these cells showed a high excretion of lactic acid.
It was therefore concluded that the energy production of tumor cells
occurs via two mechanisms: both the degradation of glucose to
lactic acid and the oxidation of glucose (49). This increased glucose
metabolism was primarily thought to be the result of increased
glucose uptake and, in fact, this altered uptake was demonstrated by
Hatanaka in experiments with murine sarcoma virus-infected
mouse cells (22). Unexpectedly, the rate of glucose metabolism
appeared not to be directly related to the glucose transport across
the cell membrane.
In the same series of experiments, Hatanaka (22) used transform-
ing cells induced by a Rous sarcoma virus infection or a murine
sarcoma virus infection and demonstrated that an increased glucose
transport over the cell membrane occurred even with non-me-
tabolisable sugars such as 2-deoxyglucose (DG). From these exper-
iments it was concluded that the increase in glucose uptake was due
to either an alteration in the glucose transport system or an
alteration in the functional nature of the membrane of transformed
cells.
An elegant experiment by the same author, described in the same
article (22), showed that cytochalasin B (an agent that inhibits
glucose transport across the cell membrane) did not block the
glucose transport in transformed cells. Hence, it was concluded that
the membrane of the transformed cells allowed ‘‘infiltration’’ of
glucose by a mechanism other than the initial sugar transport. This
‘‘infiltration’’ was considered characteristic for a transformed mem-
brane.
The altered membrane characteristics were once more demon-
strated by Martineau et al. (27). In a study with cultured normal
cells it was observed that, even during growth, a high concentration
of glucose in the medium had a ‘‘repressive’’ effect on the transport
system and that a low concentration resulted in a ‘‘derepression’’ of
glucose transport. In transformed cells, it appeared, however, that
high sugar concentrations had no repressive effect on sugar trans-
port, whereas the rates of both glucose consumption and lactic acid
production were not higher than in a control group of cells (22).
Glucose Transporters
Insulin causes muscle and fat cells to absorb glucose from the
circulation. This pancreas-produced hormone interacts with special
transporters located in the cell membrane. These transporters are
special proteins that help to convey glucose into the cell; therefore,
they are called glucose transporters. These molecules have been
thoroughly studied in human erythrocytes and are identified as
heterogeneously glycosylated integral membrane proteins (30).
There is sufficient evidence to show that the glucose molecule in
circulation binds to the outer part of the transporter protein on the
outside of the cell membrane, after which the complex changes
conformation so as to move the glucose molecule to the inside of
the membrane.
In the next step of this stereospecific process, the glucose
molecule is released into the cytoplasm, and the transporter
molecule resumes its original conformation in the membrane (Fig.
1). This transport of glucose involves hydrogen bonds between the
glucose molecule and active parts of the transporter molecule,
which ‘‘push’’ the glucose in the conveying process from the
extracellular to the intracellular space (10). This stereospecific
diffusion does not require energy, except in the case of the
transporter that is abundant in the small intestine and the kidneys.
This transporter is different from transporter molecules in other
parts of the body in that it has a special affinity for fructose (24).
This oscillation process moves glucose through the cell membrane
from the high to the low glucose concentration, and in the
erythrocyte the oscillation rate is about 900 times per second (1). It
needs to be mentioned that this transport mechanism is based on
the molecular structure of GLUT 1, which is the only protein that
could be analysed properly because it has been isolated without
functional loss. The transport mechanism as illustrated in Figure 1
is based on two different conformations of the transporter protein.
Recently, the transport behaviour of GLUT 1 with alternative sugar
import and sugar export was questioned (11).
So far, seven glucose transporters (GLUT 1–7) have been found,
all consisting of a similar polypeptide chain of 500 amino acids with
similar folding pattern (3, 4). These transporter isoforms are
distributed over various tissues: GLUT 1 is abundant in erythro-
cytes, GLUT 2 in enterocytes and liver cells, GLUT 3 in the brain,
GLUT 4 in skeletal and heart muscle, and GLUT 5 in the small
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intestine and kidney (31). GLUT 6 is nonfunctional and GLUT 7
has been found mainly in hepatocytes (3, 4, 31).
To reiterate, tumor cells display increased rate of glucose uptake
as compared to untransformed cells, and the question arises whether
this is due to increased activity of the glucose transporters, an
increased biosynthesis of these molecules, or to the generation of a
new class of transporters. Experiments performed about a decade ago
revealed that cellular transformation coincides with elevated levels
of glucose transporter messenger RNA (6, 17, 23).
In cultured fibroblasts transfected with src and ras oncogenes, it
was found that glucose uptake was increased, paralleled by an
increase in the amount of glucose transporter protein. In contrast,
in cells transfected with the myc-oncogene, the glucose uptake was
unchanged, which gives rise to the hypothesis that the origin of the
tumor plays an important role (17). Thus, there is experimental
evidence that malignant transformation results in an increased
expression of the gene encoding for the glucose transport system.
The transcription of GLUT 1 and GLUT 3 is at a higher level in
cancerous tissue than in normal tissue, and it has been suggested
that overexpression of GLUT 1 and GLUT 3 genes is responsible
for the increased uptake of glucose in malignancies (32, 53). Some
confirmation of this hypothesis has been found by the increased
expression of GLUT 1 and GLUT 3 in hepatocellular carcinoma
and several brain tumors (33, 46).
TRAPPING AND METABOLISM OF GLUCOSE AND
DEOXYGLUCOSE
When glucose enters the living cell, phosphorylation catalyzed by
hexokinase occurs. The resulting molecule glucose-6-phosphate
may enter further metabolic pathways. Glucose-6-phosphate inhib-
its hexokinase in an allosterical way, so that the uptake of glucose
by cells is dependent on the rate by which glucose-6-phosphate is
metabolized. The enzyme glucose-6-phosphate isomerase transfers
glucose-6-phosphate into fructose-6-phosphate. This isomerization
converts the aldose into a ketone through a cis-enediol intermedi-
ate. In effect, this is a rearrangement of the carbonyl group from the
C-1 to the C-2 position in the ring structure.
As with glucose, 2-deoxyglucose enters the cell and is phosphor-
ylated by hexokinase to 2-deoxyglucose-6-phosphate. Further
catabolysis of 2-deoxyglucose-6-phosphate is not possible as this
would require the presence of an oxygen atom on the C-2 position.
Thus, 2-deoxyglucose-6-phosphate is trapped in the cell and, owing
to a very low concentration of glucose-6-phosphate, the reverse
reaction does not take place. Because of these characteristics,
2-deoxyglucose can be used to investigate glucose uptake of the cell.
The increased glucose metabolism of tumor cells has been
suggested to be due to an increased activity of glycolytic enzymes
(50, 51). In 1978 Monakhov et al. (29) reported on the fact that
hexokinase played an important role in this process. It was found
that in human malignant tissue the slower isoenzymes in the
hexokinase spectrum showed a much lower abundance. Moreover,
the same authors observed that the isoenzymes in tumor tissue
showed an increased affinity for glucose.
Experiments by Bustamante et al. (9) with rat cells demonstrated
that the cytoplasm of Ehrlich ascites tumor cells showed a high
glycolytic rate compared to cytoplasm from normal liver tissue.
When the mitochondria were extracted from the cytoplasm of the
tumor cell, the aerobic glycolysis decreased, which illustrates the
association of mitochondria with hexokinase. Furthermore, the rate
of glycolysis of normal liver cytoplasm increased after the addition
of tumor mitochondria, but not after the addition of normal
mitochondria. In these experiments it also appeared that the
addition of normal mitochondria to the tumor cytosol resulted in a
glycolytic rate equal to that of normal cells. Also, it appeared that
the addition of hexokinase extracted from tumor mitochondria
resulted in an enhanced glycolytic rate.
These experiments suggest that highly active hexokinase bound
to tumor mitochondria—a phenomenon not present in normal
cells—causes the high glycolytic rate in tumor cells (2). Experi-
ments by Pulselli et al. (36) have confirmed the special nature of
hexokinase bound to the mitochondrial membrane of tumor cells.
Moreover, Fanciulli et al. (15) observed both enhanced glycolytic
and growth rates in transfected cells and ascribed this to the
relatively high hexokinase activity as a consequence of both a high
cellular metabolic demand and a more intense mitotic activity.
SCINTIGRAPHY WITH FDG IN ONCOLOGY
FDG Uptake in Relation to Pathophysiology
Local cerebral glucose consumption was measured by Sokoloff et al.
(43) in 1977 using carbon-14-labelled deoxyglucose in rat. One year
later Gallagher et al. (18) reported on the use of 18F-2-deoxy-2-
fluoroglucose (FDG) to study overall glucose metabolism in rodents.
FIG. 1. Model for alternative conformation of the glucose transporter according to Carruthers et al. (10). Stages I–III show the
import and export of the sugar molecule via the conveying glucose transporter from the extracellular to the intracellular space.
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Soon after that, tumor detection in animals with FDG was achieved
by Som et al. (44). The scintigraphic visualization of liver metas-
tases in patients was described by Yonekura et al. (54), and Patronas
et al. (34) reported on FDG accumulation in brain tumors and its
relation to tumor necrosis. Since then numerous articles have
appeared on the clinical use of FDG in oncology, and readers are
referred to recent papers by Conti et al. (12), Rigo et al. (38), and
Biersack et al. (5), discussing results in various cancers and clinical
indications.
The fact that all living cells in the human body consume glucose
interferes with the visualization of tumor tissue using FDG. High
uptake is seen in those areas with low cellular glucose-6-phos-
phatase such as the brain and the heart. In contrast, the liver and
the gut contain higher glucose-6-phosphatase levels, and in these
organs the FDG uptake is relatively low (8). The FDG uptake in
muscles is usually prominent, and this has led investigators to
prescribe complete rest for patients in order to avoid muscle artifacts
(38). Fasting, and thus hypoinsulinemia, reduces the availability of
glucose transporters and may help to lower FDG uptake in muscles.
As indicated in this report, tumor tissue contains an increased
amount of glucose transporter protein, and this phenomenon
facilitates tumor detectability under fasting conditions with relative
low uptake in the skeletal and cardiac muscle, by virtue of a higher
tumor-to-nontumor ratio. It has also been suggested that high
glucose plasma levels make FDG compete with glucose, resulting in
a decreased FDG accumulation in neoplastic cells (47).
Among other biological phenomena that play a part in FDG
accumulation in tumor cells, it is worthwhile to mention the
increased transcription of GLUT 1 and GLUT 3 together with the
presence of a highly active hexokinase isoform. This certainly helps
to enhance the FDG uptake in the tumor. In addition, relative
hypoxia, which often occurs in tumor masses, may activate the
metabolic steps in the anaerobic glycolytic pathway and enhance
FDG uptake (28), thereby contributing to an enhanced tumor-to-
nontumor ratio. In contrast, necrotic masses, which may be present
in the same tumor, reverse this enhanced ratio.
It is hardly conceivable that the processes mentioned above occur
in a controlled manner, and inter- and intra-individual cell-to-cell
variations in tumor biochemistry are therefore likely. For clinical
studies, this means that tumor FDG uptake is influenced by
biochemical phenomena of which we have only fragmentary knowl-
edge. It also explains the broad ranges between which FDG uptake
varies (5).
Nevertheless, within the scope of this report it needs to be
mentioned that FDG uptake has a high sensitivity (up to 90%) to
depict primary and secondary malignant lesions, but it has an
imperfect specificity most likely due to the nonselective uptake
mechanism. It is obvious that this radiopharmaceutical should
therefore preferably be used in carefully selected patients. Also, one
must be careful to adapt data on the accuracy of FDG scintigraphy
without question as many articles mention sensitivity and specific-
ity for lesion detection without clarifying in which way this was
verified.
Limitations of FDG Scintigraphy in Relation to
Pathophysiology
The use of FDG has often been advocated to study tumor viability.
In its ongoing effort to image regional biochemistry, nuclear
medicine should offer the potential to distinguish viable from
nonviable cancerous tissue. Does FDG measure the functional status
of a malignant lesion? The answer is definitely yes, but not without
some critical comments. The radiopharmaceutical concentrates in
metabolically active cells, thus distinguishing these from the less
active ones. As already stated, tumor cells show higher glucose
demand and can thus be differentiated scintigraphically from the
cells with less high cellular turnover.
However, tumor tissue is nonhomogeneous. First, there is a
scattered distribution of malignant tissue within the tumor. No
tumor has a homogeneous tissue structure; clusters of normal cells
alternate with clusters of (pre)malignant cells. This phenomenon
occurs at a microscopic scale far beyond the resolution of the
gamma camera. Consequently, scintigraphy with FDG measures an
average energy demand in the tumor that does not fully reflect the
metabolic status of the malignancy. This may be especially confus-
ing if one wants to evaluate the effect of therapy.
Second, as a result of repair processes induced by physiological
reactions or after tumor therapy, macrophages will replace tumor
cells, these cells will also demonstrate FDG uptake. It has even been
demonstrated that these macrophages show a higher FDG uptake
than do viable tumor cells.
The confusing FDG uptake in the inflammatory response to
tumor cells has been studied by Kubota et al. (26), who demon-
strated that surrounding macrophages and newly formed granula-
tion tissue showed greater FDG uptake than did viable tumor cells.
A maximum of about 25% of the total 18F activity measured in
tumor tissue was derived from macrophages and granulation tissues.
The clinical consequence of this has been reported by Haberkorn et
al. (20), who studied patients with colorectal tumors after radio-
therapy. Secondary inflammation following therapy induced false-
positive FDG accumulation in these tumors, thus hampering the
scintigraphic evaluation of therapy.
Third, literature on the time-dependent behaviour of FDG in
tumors is very scarce. The uptake with time is most likely
dependent on local parameters as mitotic activity and growth
rate. Therefore, the interval between FDG administration and
scintigraphy may affect the measured uptake. It may also explain
the observed variation in uptake in apparently similar tumors in
different patients (21).
Fourth, compartmental modelling requires a quantitative ap-
proach, and rate constants for a three-compartment model for
2-deoxyglucose were derived from measurements in an animal
model (43). The model has been validated in humans for FDG by
Phelps et al. (35) in 1979 by measuring the cerebral glucose
metabolic rate. The application of kinetic models assumes that
radioactivity is spread homogeneously over the tumor, which is, as
stated, rarely the case in solid tumors. This false assumption has
thrown some doubts on the validity of the method (41).
To relate the quantitative kinetic behaviour of FDG to glucose,
the lumped constant was developed and defined as the ratio of the
FDG phosphorylation rate to the glucose phosphorylation rate
under steady-state condition (37). This lumped constant appeared
not to be influenced by plasma glucose levels in the rat (42), but
may change during tumor treatment owing to physiological and
biochemical response. This was exemplified by Fischman and
Alpert (16), who elucidated the role of lysosomal acid hydrolases,
released in the process of tumor treatment and the development of
necrosis, causing further metabolism of glucose-6-phosphate. Also,
hexokinase is a major factor in the transport characteristics of FDG
and glucose. The relative activity of the various isoforms of
hexokinase changes during treatment, causing altered phosphoryla-
tion rates for FDG and glucose. These kinetic changes influence the
lumped constant and affect the evaluation of serial FDG uptake in
patients undergoing treatment.
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CONCLUDING REMARKS
Although a large number of articles have appeared on the clinical
use of FDG, only a few have paid attention to biological factors
influencing the uptake of this radiopharmaceutical (8, 16, 45).
There is no doubt that with increasing cellular transformation, the
malignant cell demands more glucose, and its requirements can be
met by the upregulation of the membrane glucose transporter
proteins. Also, the activation of enzymes involved in glucose
metabolism and the deletion of nonrelevant enzymes may help the
malignant cell to obtain the energy needed for proliferation.
Finally, it is important for nuclear medicine that FDG follows the
initial biochemical route of glucose. Despite its limitations, FDG
has served many clinical purposes and has helped to solve many
individual clinical problems. An area that deserves special attention
for future studies is the quantification of in vivo uptake of FDG. To
study this, the timing, dietary conditions, and resting protocols of
patients need to be standardized.
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